Cargando…
Use of everolimus in liver transplantation
In recent years, the use of mammalian target of rapamycin inhibitors has gained traction in their use as alternative or adjunct immunosuppressants in the post-liver transplantation (LT) setting. The efficacy of everolimus (EVR) in de novo LT is established and a reasonable time to initiate EVR is 30...
Autores principales: | Yee, Mei-Ling, Tan, Hui-Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569278/ https://www.ncbi.nlm.nih.gov/pubmed/28878864 http://dx.doi.org/10.4254/wjh.v9.i23.990 |
Ejemplares similares
-
Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
por: Uchida, Junji, et al.
Publicado: (2018) -
Advances in liver transplantation for unresectable colon cancer liver metastasis
por: Cui, Xiao, et al.
Publicado: (2021) -
Expanding indications for liver transplantation in the era of liver transplant oncology
por: Panayotova, Guergana, et al.
Publicado: (2021) -
Liver transplantation for benign liver tumors
por: Ostojic, Ana, et al.
Publicado: (2021) -
Liver transplantation and aging
por: Mikulic, Danko, et al.
Publicado: (2020)